TG Therapeutics Q4 BRIUMVI US revenue $182.7M (+20% QoQ); 2026 revenue guidance raised to $875-900M

TG THERAPEUTICS, INC.

2025-FY EPS reported $2.77 revenue$616,287,000

Q4 total revenue $192.6M; full year 2025 $616.3M; BRIUMVI US net revenue $594.1M (+92% YoY).
Net income Q4 $23.0M; full year $447.2M including $339.8M non-recurring deferred tax asset benefit.
2026 guidance: total global revenue $875-900M; BRIUMVI US net $825-850M; Q1 2026 target $185-190M.
Completed $100M share repurchase (3.5M shares at avg $28.55); new $100M buyback authorized.
Pipeline milestones: ENHANCE IV data mid-2026; subcutaneous ublituximab data year-end 2026/1Q 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.